𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy

✍ Scribed by Don M. Morris; E. George Elias; Mukund S. Didolkar; Sally D. Brown

Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
350 KB
Volume
29
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

The effect of known chemotherapeutic programs in patients with breast cancer who developed metastasis during or after adjuvant chemotherapy with L-PAM plus 5-FU (PF) were studied. Thirteen patients failed while receiving adjuvant therapy at 3-22 months from the time therapy started. Three patients failed 6-28 months after 2 years of therapy. Thirteen patients received PF followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) at the time of progression on PF. Of these, ten received Adriamycin and vincristine (AV) at the time of progression on CMF. The response to CMF was 7%. No patient responded to AV after progression on CMF. Two of three patients treated with AV after failure on PF did respond, but both for only 6 months. This suggests that adjuvant therapy may render the tumor less responsive to further chemotherapy. Since most patients failed while on adjuvant therapy, this may indicate a poor prognosis regardless of the agents used.

πŸ“œ SIMILAR VOLUMES

The cost of adjuvant chemotherapy in pat
The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma
✍ Nina Oestreicher; Scott D. Ramsey; Jeannine S. McCune; Hannah M. Linden; David L πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Abstract ## BACKGROUND In the U.S., the majority of premenopausal patients with early‐stage breast carcinoma are treated with adjuvant chemotherapy. However, to the authors' knowledge, there have been few formal analyses of adjuvant chemotherapy cost performed to date, especially in premenopaus

Responses to chemotherapy or chemohormon
Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: A subset analysis of CALGB study 8081
✍ Carl G. Kardinal; Michael C. Perry; Ann H. Korzun; Mary Alice Rice; Sandra Ginsb πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 399 KB πŸ‘ 2 views

The Cancer and Leukemia Group B (CALGB) evaluated the response to subsequent chemotherapy or chemohormonal therapy in 46 patients with advanced breast cancer treated previously with adjuvant chemotherapy that had been completed 6 months or more before protocol entry. The results were compared with 3

Monitoring the response of patients with
Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography
✍ David A. Mankoff; Lisa K. Dunnwald; Julie R. Gralow; Georgiana K. Ellis; Mariann πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 221 KB πŸ‘ 2 views

## BACKGROUND. Mammographic and physical examination assessments of the response of locally advanced breast carcinoma (LABC) to neoadjuvant therapy have been shown to be inaccurate. The authors studied the feasibility and accuracy of [technetium 99m]-sestamibi (MIBI) for monitoring the response of